Melanoma News

News

HCT treatment tied to lower cancer risk, except skin cancer

20230526110000

Treatment with hydrochlorothiazide (HCT) contributes to a lower all-cancer risk and a slightly higher skin cancer risk compared with alternative diuretics, reports a study involving a German population.

Individuals with vitiligo less prone to melanoma, skin cancer

20230508060000

The incidence of melanoma and nonmelanoma skin cancer appears to be markedly low among people with vitiligo, as reported in a study.

Second primary melanoma tied to better survival than single primary lesion

20230506110000

Patients who present with second primary melanomas have better survival and thinner lesions than those presenting with single primary melanomas, reveals a study.

Immune-related AEs predict survival in cancer patients on ICI

20230505130000

Developing cutaneous immune-related adverse events (cirAEs) among advanced cancer patients on immune checkpoint inhibitor (ICI) appears to be a sign of longer overall survival, particularly in those with melanoma, suggests a recent study.

Systemic therapies effective in melanoma of unknown primary

20230408120000

Patients with melanoma of unknown primary (MUP) benefit from novel therapies similarly as those with stage-matched melanoma of known cutaneous primary (cMKP) despite having less favourable baseline prognostic factors, reveals a study.

Pembrolizumab extends RFS in stage II melanoma

SLN status optimizes adjuvant therapy decision-making in clinical stage IIB/C melanoma

20230407120000

The performance of a prognostic model with sentinel lymph node (SLN) biopsy status in assessing patient risk for 5-year melanoma-specific death is superior to that of a model with primary tumour staging factors alone for threshold mortality rates ≥30 percent, a study has shown.

Original New Drug Application Approvals by US FDA (16-31 March 2023)

20230331000000

New drug applications approved by US FDA as of 16-31 March 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Neoadjuvant–adjuvant bests adjuvant-only pembrolizumab in advanced melanoma

20230314100000

For patients with stage III or IV melanoma, treatment with pembrolizumab both before and after surgical resection leads to longer event-free survival than treatment with pembrolizumab only after the procedure, according to the results of a phase II study.

Multiple moles, genetic predisposition up risk of second primary melanomas

20230122150000

Individuals with multiple nevi and high genetic predisposition to melanoma appear to have the highest risks of developing second primary melanomas, according to a study.

First-line pembrolizumab feasible for BRAF V600–mutant melanoma

20221110130000

A recent study recommends the use of pembrolizumab over BRAF/mitogen-activated protein kinase inhibitors, such as dabrafenib/trametinib, as first-line treatment in patients with advanced BRAF V600‒mutant advanced malignant melanoma.

Improving Medical Practice through Advancement in Clinical Treatment: IMPACT Aesthetics & Suturing Workshop 2018

Dr. Steven Ang, Dr. Leo Kah Woon, 11 Jul 2018

DCH Auriga recently held their first Aesthetics and Suturing Workshop under the IMPACT continuing medical education series – a scientific platform that aims to cascade the latest updates on disease management and share best clinical practices among healthcare professionals in Singapore. Two experts on aesthetics and aesthetic surgery shared their insights on suturing techniques and current approaches for scar prevention and management.

Product Highlight - RELIZEMA

16 Jun 2021

Furfuryl Palmitate

Product Highlight - Canespro

15 Jun 2022

Bifonazole Anti-Fungal Cream 1% w/w